Abstract 3868
Background
High-dose chemotherapy combined with autologous stem cell rescue (HDCT+ASCR) has been used to treat newly diagnosed medulloblastoma (MB), but there was no high-level evidence to support its efficacy.
Methods
Databases were retrieved, and patients were divided into two groups: group A was radiotherapy combined with HCDT+ASCR, and group B was classical radiotherapy and chemotherapy. The clinical benefit rate, progression-free survival (PFS), total survival (OS) and toxicities data were extracted.
Results
22 clinical trials met the inclusion criteria, 416 in group A and 2331 in group B. There was no difference in CBR between two groups (80.0% vs. 71.5%, P = 0.262). The 3-year PFS (3-y PFS) of group A was significantly better than group B (79.0% vs. 69.5%, P = 0.004). The analysis found that there was no difference between the two groups of the standard risk group or the high-risk group. In the standard risk group, the 5-y PFS of group A was significantly better than group B (83.6% vs.75.6%, P = 0.004). Comparison of 3-y OS and 5-y OS between two groups of all MB patients showed no difference (P = 0.086; P = 0.507), stratified analysis was the same result. The gastrointestinal toxicity in group A was significantly higher than that in group B (P = 0.016), and the level 3/4 ototoxicity in high-risk group A was higher than that in group B (P < 0.001).
Conclusions
HDCT+ASCR was not recommended for newly diagnosed high-risk MB patients. The clinical significance of HDCT+ASCR at the time of initiation in the standard risk group remains to be further explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Second Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract